Antibiotice Ia (ATB) — Capital Reinvestment Ratio
Latest as of December 2025:
0.35x
Antibiotice Ia (ATB) has a Capital Reinvestment Ratio of 0.35x as of December 2025, meaning it reinvests 0% of its operating cash flow (RON37.61 Million) in capital expenditures (RON13.33 Million). See Antibiotice Ia free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.35x
Capex / Operating Cash Flow
Operating Cash Flow
RON37.61 Million
RON
Capital Expenditures
RON13.33 Million
RON
Data as of
Dec 2025
Most recent filing
Antibiotice Ia Capital Reinvestment Ratio (2022–2025)
This chart tracks Antibiotice Ia's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Antibiotice Ia (2022–2025)
Year-by-year Capital Reinvestment Ratio for Antibiotice Ia from 2022 to 2025. For live market cap and broader valuation context, see Antibiotice Ia market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (RON) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.97x | RON72.44 Million | RON142.61 Million | ▲ +61.3% |
| 2024 | 1.22x | RON95.15 Million | RON116.16 Million | ▲ +52.5% |
| 2023 | 0.80x | RON122.46 Million | RON98.04 Million | ▲ +132.2% |
| 2022 | 0.34x | RON115.66 Million | RON39.88 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow